cFluor™ B532 Anti-Human CD73 (AD2)
The AD2 monoclonal antibody binds to human CD73, a 70-kDa glycosyl phosphatidylinositol (GPI)-linked 5’-nucleotidase. CD73, also known as ecto-5’-nucleotidase, has enzymatic activity to convert extracellular adenosine 5’-monophosphate (AMP) to adenosine1,2. It is present in subsets of both T and B cells and at high level on B cells3. It is also expressed on mesenchymal stem cells, follicular dendritic cells, epithelial cells and endothelial cells. The antibody was conjugated to a fluorophore and puriﬁed by afﬁnity chromatography.
Reactivity: Human, Baboon
Format: cFluor™ B532*
Isotype: Mouse IgG1, κ
Tested Dilution: 5 μL / test
Application: Flow Cytometry
Storage: 2-8°C and protected from Light. Do not freeze.
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% BSA (Origin USA)
Each lot of this antibody is quality control tested using flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µL per 1 million cells in a staining volume of 100 µL. If whole blood is analyzed, then use 5 µL per 100 µL. It is recommended that users titrate the antibody to obtain the optimal result for their specific application.
- Thomson LF, et al. 1990. Tissue Antigens. 35(1):9-19.
- Antonioli L, et al. 2013. Trends Mol Med. 19(6):355-367
- Minor M, et al. 2019. Am J Physiol Cell Physiol. 317(6):C1079-C1092
These products are for research use only. Not intended for use in diagnostic procedures.
*cFluor™ B532 is equivalent to CF®503R manufactured and provided by Biotium, Inc. under an Agreement between Biotium and Cytek (LICENSEE). The manufacture, use, sale, offer for sale, or import of the product is covered by one or more of the patents or pending applications owned or licensed by Biotium. The purchase of this product includes a limited, non-transferable immunity from suit under the foregoing patent claims for using only this amount of product for the purchaser’s own internal research. No right under any other patent claim, no right to perform any patented method, and no right to perform commercial services of any kind, including without limitation reporting the results of purchaser's activities for a fee or other commercial consideration, is conveyed expressly, by implication, or by estoppel.